Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
Authors:
- 1 November 2017
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 30 (11) , 1516-1526
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other MalignanciesCancer Research, 2016
- Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodiesJournal of Translational Medicine, 2016
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisLeukemia, 2016
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic CholangiocarcinomaClinical Cancer Research, 2016
- Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In VivoClinical Cancer Research, 2014
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization ArrayClinical Cancer Research, 2009
- Triple-Negative Breast Cancer: Risk Factors to Potential TargetsClinical Cancer Research, 2008
- Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedJournal of Clinical Oncology, 2008
- High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarraysNature Genetics, 1998
- HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Journal of Clinical Oncology, 1997